VivoSim Labs, Inc. (VIVS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, VivoSim Labs, Inc. (VIVS) has a cash flow conversion efficiency ratio of -0.337x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.38 Million) by net assets ($7.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
VivoSim Labs, Inc. - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how VivoSim Labs, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read VIVS total debt and obligations for a breakdown of total debt and financial obligations.
VivoSim Labs, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of VivoSim Labs, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Magnetite Mines Ltd
AU:MGT
|
-0.030x |
|
NEWLOX GOLD VENTURES
F:NGO
|
N/A |
|
Abacus Mining and Exploration Corp
V:AME
|
0.003x |
|
BIOVAXYS TECHNOLOGY CORP.
F:5LB
|
N/A |
|
Green Cross Holdings Preference Shares
KO:005257
|
-0.014x |
|
International Biotechnology Trust plc
LSE:IBT
|
0.126x |
|
AltynGold plc
LSE:ALTN
|
0.201x |
|
Pearl Polymers Limited
NSE:PEARLPOLY
|
-0.101x |
Annual Cash Flow Conversion Efficiency for VivoSim Labs, Inc. (2011–2025)
The table below shows the annual cash flow conversion efficiency of VivoSim Labs, Inc. from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see VIVS stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $10.49 Million | $-9.46 Million | -0.902x | +77.84% |
| 2024-03-31 | $3.60 Million | $-14.65 Million | -4.069x | -402.71% |
| 2023-03-31 | $15.33 Million | $-12.41 Million | -0.809x | -189.28% |
| 2022-03-31 | $30.21 Million | $-8.45 Million | -0.280x | +17.68% |
| 2021-03-31 | $39.20 Million | $-13.32 Million | -0.340x | +39.17% |
| 2020-03-31 | $26.63 Million | $-14.88 Million | -0.559x | +0.45% |
| 2019-03-31 | $36.30 Million | $-20.38 Million | -0.561x | +13.27% |
| 2018-03-31 | $44.59 Million | $-28.86 Million | -0.647x | -38.30% |
| 2017-03-31 | $62.36 Million | $-29.18 Million | -0.468x | +0.91% |
| 2016-03-31 | $62.18 Million | $-29.37 Million | -0.472x | -17.34% |
| 2015-03-31 | $48.70 Million | $-19.60 Million | -0.403x | -24.90% |
| 2014-03-31 | $48.28 Million | $-15.56 Million | -0.322x | -117.63% |
| 2013-03-31 | $-5.30 Million | $-9.69 Million | 1.828x | -89.28% |
| 2011-03-31 | $-6.42K | $-109.42K | 17.052x | -- |
About VivoSim Labs, Inc.
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucida… Read more